Related references
Note: Only part of the references are listed.
Article
Geriatrics & Gerontology
Hubert Blain et al.
Summary: This study aimed to measure antibody decay after 2 doses of BNT162b2 vaccine and antibody response after a third dose administered 6 months later in nursing home residents with and without prior COVID-19. The results showed a rapid decay of RBD-IgG levels after the second dose and an increase in antibody response after the third dose, validating the recommendation of a third dose in residents less than 6 months after the second dose.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
(2022)
Article
Immunology
Angela Marie Abbatecola et al.
Summary: The COVID-19 pandemic has significantly impacted routine care for older individuals, particularly those living in long term care facilities. The vaccination of older adults in LTC facilities against COVID-19 is crucial in protecting them from infection and death. The GeroCovid Vax study in Italy aims to investigate the safety and efficacy of anti-SARS-CoV-2 vaccines in this population.
Article
Medicine, General & Internal
Noam Barda et al.
Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.
Article
Medicine, General & Internal
Edward H. Livingston
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Critical Care Medicine
Gregory Milne et al.
Summary: Protective immune response lasts for approximately 5-12 months, making reinfection more likely. Markers of humoral and cell-mediated immune memory can persist over many months, helping to mitigate against severe disease.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Health Care Sciences & Services
Paul Naaber et al.
Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Multidisciplinary Sciences
Thomas W. McDade et al.
Summary: The two-dose mRNA vaccines against SARS-CoV-2 are effective in preventing COVID-19 infection, but there is a decline in antibody levels and reduced neutralization of emerging variants three months post-vaccination, indicating the need to identify correlates of clinical protection for booster vaccination timing and indications.
SCIENTIFIC REPORTS
(2021)
